JOURNAL ARTICLE
Long-term results of isotretinoin in the treatment of 68 patients with hidradenitis suppurativa.
Journal of the American Academy of Dermatology 1999 January
BACKGROUND: Oral isotretinoin has been used to treat mild to severe hidradenitis suppurativa (HS).
OBJECTIVE: We reviewed the results of low-dose isotretinoin for 4 to 6 months in the treatment of 68 patients with HS.
METHODS: This is a retrospective study. Data are presented in terms of response rate, long-term follow-up, and the relation between response rate and severity.
RESULTS: In 16 patients (23.5%), the condition completely cleared during initial therapy and 11 patients (16.2%) maintained their improvement during the follow-up period. Treatment was more successful in the milder forms of HS.
CONCLUSION: Monotherapy with isotretinoin for patients with HS usually has a limited therapeutic effect.
OBJECTIVE: We reviewed the results of low-dose isotretinoin for 4 to 6 months in the treatment of 68 patients with HS.
METHODS: This is a retrospective study. Data are presented in terms of response rate, long-term follow-up, and the relation between response rate and severity.
RESULTS: In 16 patients (23.5%), the condition completely cleared during initial therapy and 11 patients (16.2%) maintained their improvement during the follow-up period. Treatment was more successful in the milder forms of HS.
CONCLUSION: Monotherapy with isotretinoin for patients with HS usually has a limited therapeutic effect.
Full text links
Trending Papers
Management of Hemorrhagic Shock: Physiology Approach, Timing and Strategies.Journal of Clinical Medicine 2022 December 30
New antibiotics for Gram-negative pneumonia.European Respiratory Review : An Official Journal of the European Respiratory Society 2022 December 32
Migraine.Annals of Internal Medicine 2023 January 11
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app